Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.062 | 0.7 |
mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.7 |
mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.044 | 0.7 |
mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
mRNA | AMG-706 | GDSC1000 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |